Life Sciences Archive » July, 2023

Life Sciences - July, 2023

330 articles

• Bristol-Myers, AstraZeneca Agree To End Drug Patent Fight
• Dog Food Labeling Suit Sent Back To Mo. State Court
• NY Judge Won't Lift Asset Freezes In Gilead Counterfeit Suit
• Shkreli-Tied Pharma Co. Clinches $650K Stalking Horse Bid
• DEA 'Set A Trap' For Opioid Sellers, AmerisourceBergen Says
• Green Groups Press EPA To List New Toxic Pollutants
• Mass. Biotech Co. Hit With Stock Drop Suit Over New Drug
• Ala. AG Hit With Suit Over Out-Of-State Abortion Help
• GAO Raps Biz For Waiting On Calls To Launch Protest
• The Children's Place Sued Over PFAS In School Uniforms
• Abortion Rights Referendum Challenged In Ohio's High Court
• 11th Circ. Ruling May Impede Insurers' Defense Cost Recoup
• Indivior Ruling May Affect Rebate Wall Litigation
• Anesthesiologist Cleared Over Instagram Surgery Video
• Catching Up With Delaware's Chancery Court
• Natera Says Rival Infringes Cancer Testing Patents
• 4 Firms Guide €1B Sale Of Controlling Stake In MedTech Biz
• Labcorp Can't Beat Retirement Plan Mismanagement Suit
• Dinsmore & Shohl Adds Three-Atty Employment Team In LA
• The Compliance Chiefs Who've Faced Legal Hot Water In '23
• Syneos Health Covered Up COVID-19 Turmoil, Investor Says
• Sequenom Beats Suit Over $371M Sale To LabCorp, For Now
• HIV Patients Can Amend Disability Bias Suit Against CVS
• Tivity Appeals Nutrisystem Merger Investor Class Cert, Again
• US Trustee Asks Supreme Court To Pause Purdue Ch. 11 Plan
• FDA Warns Distributors Over Popular, Unauthorized E-Cigs
• Pharma Group Sues Over La.'s Revisions To Drug Pricing
• Don't Miss It: Kirkland, Simpson Thacher Lead Week's Deals
• J&J Again Fails To Get Talc Claims Handled In Bankruptcy
• Atty Fees Sought For $108M Cooley Malpractice Suit In NJ
• UK Litigation Roundup: Here's What You Missed In London
• Cravath, Vinson & Elkins Steer Biogen's $7.3B Reata Buy
• Trending At The PTAB: Claim Substitution And APA Control
• Dignity Is Immaterial In Instagram Surgery Row, Jury Hears
• Allergan Asks 2nd Circ. To End Investors' Breast Implant Suit
• 5 AGs Urge JPML To Group Gov't Insulin Pricing Suits
• DEA Runs Internal Proceedings In A 'Star Chamber,' Atty Says
• Boston Scientific Says Stock Buys DQ Hopeful Lead Plaintiff
• PTAB Cuts Bone Fusion IP From Del. Suit Against Zimmer
• Aetna Can't Decertify ERISA Class Using 9th Circ. Ruling
• GOP Lawmaker Blasts FDA For Inaction On Regulating CBD
• 2 Medical Businesses End $158M IP War Over Surgical Clips
• 6th Circ. Tosses Suit Over Live Woman Brought To Embalmer
• Regenerative Med Cos. To Merge For $65M
• Mylan's Litigation Costs Are Tax Deductible, 3rd Circ. Rules
• Mallory Gives Plaintiffs A Better Shot At Justice
• FTC Cuts Deal Ending Surescripts Monopoly Case
• Ex-Aegerion Rep Says Top Court Ruling Dooms ID Theft Case
• Fitness Trainer's Disability Bias Suit Gets Green Light For Trial
• 22 States Fight 3M's $12.5B 'Forever Chemicals' Settlement
• Fearing $10B FCA Loss, Teva Seizes On Kickback Circ. Split
• Patient Says Instagram Video Caused Emotional Distress
• Cancer Group Targets 'Wrong' HHS Prescribing Limits
• 3 Takeaways From Biden's Mental Health Parity Proposal
• Why Justices' SuperValu Ruling Wasn't Quite A 'Seismic Shift'
• Expect More Mental Health Parity Guidance, DOL Official Says
• Novartis Direct Buyers' Attys Get $42M In Drug Delay Case
• White House Tells 5th Circ. Social Media Order Unprecedented
• Michigan Atty Charged With Smuggling Drugs Into Prison
• Cannabis Cos. Must Heed PFAS Risks In Products, Packaging
• These Firms Have The Most Diverse Equity Partnerships
• UK Billionaire Lewis Denies Insider Trading, Gets $300M Bond
• CORRECTED: N.J. Justices Back New Mesh Trial For C.R. Bard
• ​​​​​​​Saudi Co. Freed From Breach Suit, But Sanctioned
• Director Picks Up PTAB Denial Over Hormone Treatment
• Insurer Owes $91M For Sterigenics Pollution Suits Defense
• Bausch Must Face Suit Alleging Eye-Implant Complications
• On Deck In JPML: Insulin Pricing, Bard Catheters, Southwest
• Eli Lilly Resets Merger Review Clock On $2.4B Deal
• Chancery Approves Amneal Settlement, $1.88M Atty Fee
• 9th Circ. Axes 'Take-Home' COVID Suit, Citing Calif. Justices
• Elanco's Free Dinner Faxes Don't Trigger TCPA, 7th Circ. Rules
• Teva Exits Cancer Drug IP Row With 2031 Generic License
• Providers Look to Block 'Irrational' Parts Of NC Abortion Law
• RFK Jr. Joins States' Suit Over Biden Social Media Issue
• Ex-Client Owes McCarter & English $1M For Bills, Jury Finds
• Scarinci Hollenbeck Hires Real Estate Pro In New Jersey
• Law360's Diversity Snapshot: What You Need To Know
• Rising Star: White & Case's James Hu
• Biden Admin Unveils Proposed Mental Health Parity Regs
• High Court Didn't Shrink Kickback Law's Scope, DOJ Insists
• 11th Circ. Freezes CoolSculpting User's Product Liability Suit
• 3rd Circ. Backs Dismissal Of Heart Medication Warning Claim
• Biotech Co. Can't Defend Fundraising Claims, SEC Says
• Mass. Telemed Cos. Owner To Admit To $44M Medicare Scam
• Fed. Circ. Won't Touch A Del. Ruling On Hypertension Drug
• L'Oreal, Other Cos. Get Review In Georgia Hair Relaxer Case
• Product Liability Regulation & Legislation To Watch At Midyear
• Biden Threatens Veto Of 2024 VA, Ag. Bills Over Funding Caps
• P&G Slams 'Implausible' Detergent Greenwashing Suit
• SEC Says 2nd Stock Fraud Trial For Conn. Atty Isn't Needed
• ICE Can't Pass Off Responsibility Of Man's Death, Son Says
• Library Of Congress Asks DC Circ. To Keep Fair Use Suit Axed
• Judge Temporarily Halts IQVIA Deal At FTC's Behest
• Feds, Insider Trading Suspect Spar Over BigLaw Binder Info
• Insurance Insights From 5th Circ. Blue Bell Coverage Ruling
• Cozen O'Connor Names Canadian Life Sciences Head
• Fruit Co. Says Tribe's CWA Claims Should Be Tossed
• Courts Can Overturn Deficient State Regulations, Too
• Rising Star: Sullivan & Cromwell's Brad King
• The Litigation Jolting Health & Life Sciences In 2023's 2nd Half
• J&J Lands $18M Judgment In Counterfeit Surgical Tools Suit
• 10th Circ. Won't Revive Suit Over Janssen's Levaquin
• ​​​​​​​FTC Says To Ignore Its Previous Guidance About PBMs
• Lab Exec Targets Insurers For $1B After Beating DOJ Case
• Pot Cos. Try To Move Toxic Chemical Claims To Arbitration
• Judge OKs Deal Ending Pa. 'Your CBD Stores' Lawsuit
• AbbVie Gets Amicus Backing In 2nd Circ. Bystolic Suit
• Panel OKs Bill To Study Developing Drugs Without Patents
• Life Sci Cos. Should Work With FDA To Shape AI Regulation
• AstraZeneca Trims Sex Harassment Retaliation Suit
• Health Hires: Kleinfeld Kaplan, Michael Best, Creyon
• FTC Tries To Cut Amgen, Horizon's Constitutional Challenge
• Blackstone's 5 Biggest Bets As Firm Tops $1T In Assets
• Trustee To Take Over Estate In Molecular Dynamics Ch. 11
• UK Litigation Roundup: Here's What You Missed In London
• Rising Star: Hyman Phelps' James Valentine
• Tales From The Trenches Of Remote Depositions
• Texas Witness Says Abortion Ban Confusion Sowed By Media
• Last Claims Tossed In McKinsey Opioid Marketing MDL
• 3rd Circ. Backs Axing Pharma Execs' Conspiracy Charge
• Ex-Med. Device Co. Worker Cops To Faking FDA Clearances
• Employer Groups, Insurers Fight For 'No Surprises' Law
• UK Drug Co. Settles For $19.6M Over False Safety Claims
• Shkreli Not Aided By Top Court's 'True Threat' Case, AGs Say
• Illinois Cases To Watch In 2023: A Midyear Report
• Costco Accused Of Destroying Evidence In Contact Lens Suit
• A Practical Solution To Life Sciences Joint Venture Disputes
• Endo International Wins More Support For $6B Ch. 11 Sale
• Deals Rumor Mill: Ramsay Sime Darby, THL, Roivant
• 2023 Is Far From Done With Government Merger Cases
• Rising Star: WilmerHale's Timothy Cook
• Endo Pitches Deal With Distributors Over Ch. 11 Sale Plan
• Texas Abortion Ban Has 'No Mercy' For Suffering, Judge Told
• MetLife Beats ERISA Suit Alleging It Withheld Drug Rebates
• FTC Judge Calls Simultaneous In-House, Fed Cases 'A Waste'
• Pension Fund Says It Lost $33.6M Over Pharma Co.'s Actions
• Pfizer Settles Conn. Trade Secrets Case Against Ex-Execs
• 5 Patent Cases To Watch In The Second Half Of 2023
• Sorrento Asks For Stay Of Employment Suit Against CEO
• Flint Engineering Firm Must Turn Over Media Strategy Docs
• Juul Says It's Seeking FDA OK For New E-Cig Device
• How Life Sciences And Education Industries Can Partner Up
• Employer Drug-Testing Policies Must Evolve With State Law
• Crowell Urges Delay In Walgreens-Humana Conflict Ruling
• TPG To Pay $1.4B For Nextech As Part Of Health Care IT Push
• Biggest Illinois Decisions Of 2023: A Midyear Report
• Tide May Be Turning On Texas Two-Step Bankruptcy Strategy
• Rising Star: Ropes & Gray's Suni Sreepada
• Calif. Justices Open Door To Nonprofits, Unions Suing Cos.
• Danaher Played Down Post-COVID Slump Risk, Investor Says
• GreenLight Shareholders Sue In Del. For Company Books
• J&J Unit Launches 6th Challenge To Drug Price Negotiations
• ​​​​​​​J&J Owes $19M To Cancer Patient In Calif. Talc Trial
• SEC Fines Ex-Merck Regulatory VP For Insider Trading
• Troutman Pepper Adds New Cannabis Partner In NC
• Iowa Judge Halts 6-Week Abortion Ban Amid Challenge
• NY Towns Object To 3M's $12.5B 'Forever Chemicals' Deal
• Pa. Judge Affirms Nixing Of Expert Testimony Over Autism
• Eli Lilly Worker Urges Class Certification In Age Bias Suit
• 7 Trials To Watch In The Second Half Of 2023
• Talc Claimants' Rep. Slams 'Outrageous Antics' In DQ Bid
• CBD Co. Wants Counterclaims Nixed In Epidiolex Patent Row
• DC Sues 3M, DuPont, Others Over 'Forever Chemicals'
• Lewis Brisbois Adds Gov't Affairs Partner, Ex-Sidley Leader
• Judge Nixes Damages From $45M Natera False Ad Verdict
• Erika Jayne Meets Face-To-Face With Girardi's Alleged Victims
• Pennsylvania Cases To Watch In 2023: A Midyear Report
• Damages Ruling Ups Stakes In FCA Kickback Case Against Teva
• FTC Moves To Block IQVIA Deal Over Health Ad Concerns
• Astellas Says Drug Price Negotiation Law Is 'Unconstitutional'
• The Biggest Patent Rulings Of 2023: A Midyear Report
• FTC Seeks Pause Of $28B Amgen Deal Amid Challenge
• 1st Trial Down In Abbott's Patent War In Delaware
• Blunders That Made 'Bakked' Cannabis TM Go Up In Smoke
• $255M Juul Deal Doesn't Address Addiction, Objectors Say
• Texas Atty Convicted For Role In Medical Kickback Scheme
• Westlake Village BioPartners Launches $450M Fund
• Justices Quietly Added Ammo To Big Pharma's Kickback Blitz
• McKesson Investor Attys Get $35M For $141M Price Fix Deal
• 5th Circ. Pauses Limits On Biden Admin Social Media Collabs
• PTAB Can't Interfere With AIA Patents, Fed. Circ. Says
• DEA Must Produce Data For Opioid MDL Trials, Judge Rules
• Sorrento DIP Lender Opposes Short-Selling Settlement
• Electronic Health Records Co. To Pay $31M To End DOJ Suit
• Opioid Distributor Takes Cherokee Case To Federal Court
• Nerve Stimulator Co. Again Beats Investor Suit Over $78M IPO
• Challenging Standing In Antitrust Class Actions: Timing
• Trustee Wants Out Of Suit Over Radiology Co.'s ESOP
• Health Hires: Venable, McDermott, Arbutus
• Strategies For Patent Drafting As Eligibility Questions Linger
• 3 Firms Steer Upsized Biotech IPOs Raising $385M Combined
• Level Up Lawyers' Business Development With Gamification
• UK Litigation Roundup: Here's What You Missed In London
• Eli Lilly Buying Obesity Drugmaker Versanis In Near-$2B Deal
• Republican AGs Warn CEOs About Bias After Harvard Ruling
• 'Ridiculous': Texas Judge Unloads On Biden's Abortion 'Fiats'
• AIA Challenges To Drug Patents Are Down, USPTO Finds
• Gov't Takes 'No Surprises Act' Challenge To 5th Circ.
• Court Won't Cut Pre-2009 Smith & Nephew Hip Implant Claims
• FTC Nears Deal To End Surescripts Monopoly Case
• 11th Circ. Says Insurers Can't Recoup Drug Co.'s Suit Costs
• Baxter Hid Supply Chain Woes From Shareholders, Suit Says
• Mich. Blasts $5M Fee Ask In Flint Water Case As 'Overreach'
• 2nd Circ. Revives Niagara Falls Radioactive Waste Claims
• Holmes, Kapoor Aided By Push To Curb Prison Time
• Addressing Legal Issues Raised By AI Use In Health Care
• Mallory Ruling Leaves Personal Jurisdiction Deeply Unsettled
• Vancouver Man Extradited To Face Stock Fraud Charges
• Talc Claimants' Rep. Faces DQ Bid Over Dinner With J&J Atty
• DEA Wrongly Refuses To Reconsider Psilocybin, 9th Circ. Told
• Boston Scientific Pelvic Mesh Case Settled Ahead Of Trial
• Shkreli Argues 'True Threat' Case Backs Lifting Pharma Ban
• FDA Clears Over-The-Counter Birth Control Pill
• 3M Calls Bid To Disqualify MDL Judge 'Gamesmanship'
• 2nd Circ. Cites Misjudged Impact Of Deficient Immigration Atty
• AmerisourceBergen Investors Pan Drug-Dregs Suit Report
• Texas DAs' Abortion Silence Bars Outsiders' Help, Groups Say
• IP Toolbox Is Crucial In AI-Powered Drug Discovery
• Court Tosses AstraZeneca's Challenge To USPTO's Fintiv Rule
• Worker Says LifePoint's Bid To Duck Wage Suit Is Premature
• Singapore's Quadria Selling FV Hospital Stake For $381M
• 5 Ways Firms Can Rethink Office Design In A Hybrid World
• Illumina Fined €432M For Closing Grail Deal Without EU OK
• Holmes Free In 2032? Agency Projects Release 2 Years Early
• Client Hailed McCarter & English Before Malpractice Claim
• Merck Cites 'Gulag,' Jeers HHS 'Backtracking' As Suits Surge
• Travelers Units Beat Blue Bell Coverage Suit At 5th Circ.
• Mich. Panel Skeptical State Can Salvage PFAS Rules
• Judge Calls Drugmaker's Bid To Strike 'A Bit Disingenuous'
• Ag. Board Says Union Isn't Bona Fide Org. Under Calif. Law
• Express Scripts Fights Acthar Antitrust Class Cert. Bid
• 11th Circ. Won't Revive Pension Fund's Suit Against MiMedx
• A Midyear Look At How AI Is Affecting Lawyers
• CSX Shouldn't Escape Asbestos Claims, Widow Says
• NJ Town Illegally Barred Pot Cos. Development, Suit Says
• Philips Says CPAP MDL Shows No Exposure To Foam Toxins
• Wilson Sonsini Hires Former Biotech GC As Client Adviser
• Psychedelics Litigation To Watch In 2nd Half Of 2023
• Bar Score Is Best Hiring Metric Post-Affirmative Action
• Same Judge To Hear Atty's 2nd Trial After Jury Poll Gaffe
• Defense Counsel Sentencing Lessons From Holmes Case
• Biden Admin Can't Pause Social Media Order During Appeal
• J&J Could Have Saved Talc User In '90s, Jury Hears
• Abbott, Mead Get Tentative Win In Suit Over Infant Formula
• Full 11th Circ. Sends Ga. Doc's Roundup Case Back To Panel
• Mallinckrodt Hit With Investor Suit After Mulling 2nd Ch. 11
• Colo. Biotech Buyout Spawns Stock Fight With Researcher
• Alexion Trial Starts Over Ditched Drug Worth 'Billions'
• McCarter & English Client Didn't Notice Rate Hikes, Jury Hears
• Ex-Pot Co. Worker Says COVID Masking Suit Must Proceed
• Ex-Choate Patent Pro Makes Move To Dechert
• Philips Cites Federal Preemption To Sink CPAP MDL Claims
• USPTO Efforts On Patent Bar DEI Miss Underlying Issues
• FDA Trends Show Compliance Priorities For Supplement Cos.
• Bayer Hits Supplier With $12M Benzene Contamination Suit
• AI-Based Pharma Co. Faces Investor Suit Over Study Woes
• Robbins Geller To Lead Amgen Investors In $10B Tax Bill Suit
• Fed. Circ. Probes Predictability Of Hair Loss Treatment Patent
• Catching Up With Delaware's Chancery Court
• Medtronic Wants Fed. Circ. To Rethink Catheter IP Decisions
• Former Gilead GC Rejoins Gunderson Dettmer In Calif.
• Fed. Circ. Says PTAB Ruling Was 'Infected By Error'
• Israel's Oddity Tech Leads 3 IPOs That Could Net $625M Total
• Zurich Unit Says $3.7M Lab Fire Suit Must Go To Trial
• Conn. Atty Says SEC 'Detached From Reality' In Judge Spat
• DOJ Lambastes Idea Of '3-Part Test' In High Court FCA Ruling
• HHS Floats $9B Drug-Discount Fix After High Court Loss
• Split PTAB Invalidates Some Leukemia Drug Patent Claims
• Ruling Conflicts With 'Day'-Old Fed. Circ. Precedent, Biz Says
• DaVita Nurses Win Partial Cert. In Meal Breaks Suit
• Delaware Judge Axes Novartis Patent On Heart Failure Drug
• Nurse Says Hospital's Bid To Shake Wage Suit Is Delay Tactic
• Pot Co. Manager Says Owner's Cross Claims Must Be Tossed
• LTL Again Takes Aim At Doctors Linking Talc To Mesothelioma
• Venture-Backed Startups Cinch Belts To Survive Lean Times
• 9th Circ. Won't Undo FDA's Denial Of Vape Applications
• Novo Nordisk Hits Pharmacies With Suits Over Ozempic
• Del. Chancery Calls For Progress In NuVasive-Alphatec Suit
• Engineering Co. Reaches Tentative Deal On Flint Water Claims
• Montgomery McCracken Attys Sued For Abuse Of Process
• DOJ's Merger Record Improves & Other Early 2023 Highlights
• Ghosting In BigLaw: How To Come Back From Lack Of Feedback
• UK Litigation Roundup: Here's What You Missed In London
• Novartis Wins Judgment In Mylan Heart Drug Patent Fight
• FDA Alzheimer's Drug OK Opens Door To Medicare Coverage
• IP Pro Returns To Kasowitz After Brief Greenberg Traurig Stint
• Philly Children's Hospital Wants End To COVID Vax Bias Suit
• Pharma Cos. Urge High Court To Toss Terror-Funding Ruling
• Bausch & Lomb Pays $106M For J&J Eye Drop Line
• Mitigating Risks Of Developing Drugs And Devices With AI
• Thermo Fisher Pays $912M For Ropes-Led Health Data Co.
• Attys Seek $2M For Pharma Biz Suit Settlement In Del.
• Mass. Justices Affirm Time Limit On Smoking Death Claims
• Cooley Life Sciences Pro Jumps To Arnold & Porter In LA
• Paul Hastings Hires 2 Ex-Goodwin Attys To Head Practices
• FCA Defense Bar Tries Flipping Script On High Court Ruling
• 9th Circ. Revives Ariz. Co.'s IP Fight With NY Amazon Resellers
• SEC Fines COVID Test Maker, Execs Over Disclosures
• Generic-Drug Makers Challenge Minn. Price Control Law
• FTC Drops Case Over Altria's Unwound Juul Investment
• How A 3-Firm 'Joint Effort' Beat A $3.6B Pharma Antitrust Suit
• Fed. Circ. Revives Bovine Sperm Sorting Patent Feud
• Sorrento Therapeutics Cleared For New $20M Loan In Ch. 11
• FDA And FTC Crack Down On THC 'Copycat' Snacks
• Flint Class Says Engineers Owed Duty To Them, Not Just City
• Product Liability Cases To Watch: 2023 Midyear Report
• Steps To Success For Senior Associates
• Feds Drop Appeal In Suit Over Trans Care Policy
• DuPont Poisoned Cape Fear River With PFAS, Suit Says
• Can M&A Bounce Back After Dismal First Half Of 2023?
• Abbott Reups Glucose Monitor Patent Spat With Dexcom
• Waymaker Found Path To Penile IP Win Via Defendant Exam
• FTC Wades Into Medtronic Surgical Device Antitrust Spat
• Brita IP Win Dampened By Commission Review
• Humira Rivals Finally Flood Market After 'Patent Thicket' Saga
• 3 Takeaways From The Supreme Court's Session
• Sun Infringes Orexo's Opioid Addiction Drug IP, Judge Rules
• Law360 Podcasts Untangle A Week Of Blockbuster Rulings
• Paul Hastings Accused Of Causing 'Demise' Of GenapSys
• The Sharpest Dissents From The Supreme Court Term
• The Funniest Moments Of The Supreme Court Term
• Jackson Debuts As Chattiest Justice
• Judge Cites 'Patent Misuse' In Ending Bard's $52M Lawsuit
• Sorrento Therapeutics Seeks New $20M DIP Loan
• Legal Profession Must Do More For Lawyers With Disabilities
• Breaking Down The Vote: The High Court Term In Review
• The Firms That Won Big At The Supreme Court
• Tax Claim Shows Injury In Pharmacy Breach, 1st Circ. Says
• Trending At The PTAB: Disclaiming A Design Claim